Kowalski, Mark Marion — Insider Profile

Insider Profile

Kowalski, Mark Marion

$EPRX

Companies Filed At

Open-Market Buys (2yr)

—

Buy Value (2yr, open-market)

Dec 15, 2025

Most Recent Trade

Credibility
Score

67%

Hit Rate

+4.9%

Avg 90d Return

+2.7%

Median 90d Return

Evaluated Trades

+18.4%

Best Trade

-6.3%

Worst Trade

Hit rate and returns are based on 3 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.

Date	Company	Role	Nature	Dir.	Shares	Price	Value	Score
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	26,000	$8.63	$224K	60
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	26,000	$8.63	$224K	60
Mar 25, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	60,000	$5.14	$308K	60
May 13, 2024	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	70,000	$3.96	$277K	60
Aug 18, 2023	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Sell	8,000	$7.00	$56K	60
May 18, 2023	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	180,000	$6.84	$1.2M	60

Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Signal scores reflect the company's current score, not the score at time of trade.